# MHRA Type: organization Source: GetYourBrief — https://getyourbrief.com/entity/mhra-organization Canonical HTML page: https://getyourbrief.com/entity/mhra-organization ## Timeline - **2027-01-01**: Target Implementation — Proposed date for the law to take full effect across the NHS and MHRA frameworks. - **2026-09-10**: Committee Stage — Detailed line-by-line examination of the bill in the House of Commons. - **2026-07**: First Patient Fulfillment Expected — Private providers anticipate delivering the first courses of the oral medication to patients by early July 2026, though the exact date may vary. - **2026-06-15**: Committee Review — Expected date for health select committee to begin detailed scrutiny of the bill. - **2026-06-12**: MHRA Approves Oral Wegovy — The UK's Medicines and Healthcare Products Regulatory Agency licenses the daily semaglutide pill for private prescription, setting eligibility criteria based on BMI. - **2026-06-12**: Private Pharmacies Begin Taking Orders — Boots, Superdrug, Morrisons and other licensed retailers start selling the Wegovy Pill on the same day as approval, with demand pushing waiting lists towards 100,000. - **2026-05-15**: Public Consultation — Opening of the consultation period for healthcare providers and biotech stakeholders. - **2026-04-01**: Expected Appeal Date — Final appraisal committee meeting to review new evidence and potential Managed Access Agreements. - **2026-03-25**: Black Market Surge — Current reports highlight the critical risk of black market drugs due to the blurring of medicine and cosmetics. - **2026-03-06**: National Campaign Launch — Bereaved family and patient advocates launch a coordinated media campaign imploring the NHS to reconsider. - **2026-02-27**: Draft Bill Introduced — The UK Government unveils the draft Rare Cancers Law targeting incurable tumors. - **2026-02-27**: Draft Law Unveiled — The Rare Cancers Law is formally introduced as a draft to Parliament. - **2026-02-19**: Official Reporting — MHRA and GOV.UK release data confirming the surge in neurotech and AI testing activity. - **2026-01-15**: NICE Initial Review — NICE issues a preliminary recommendation against routine funding based on cost-effectiveness. - **2025-12-31**: Record Achievement — Total CINs for the year reach 137, a new historical high for the agency. ## Recent coverage (9 stories, network-wide) ### Wegovy Pill Approved With 87% of Patients Losing ≥5% Body Weight 2026-06-15 08:00:50 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3 The MHRA approval of Novo Nordisk's oral semaglutide for obesity triggers a private prescribing boom, with pharmacies reporting 100,000 on waiting lists. The pill shows 87% of adherent patients in trials lost at least 5% body weight, with one in three losing 20%+. NHS discussions are under way, but no coverage timeline is set, leaving patients to navigate private costs. Full story: https://gethealthbrief.com/story/wegovy-pill-mhra-approval-87-percent-weight-loss ### Oral Semaglutide 25mg Shows 16.6% Weight Loss in OASIS-4 Trial 2026-06-15 08:00:39 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3 Novo Nordisk's oral Wegovy achieved 16.6% mean weight loss at 64 weeks in the Phase III OASIS-4 trial, with 87% of participants losing ≥5% and one-third losing ≥20%. The once-daily pill uses a SNAC absorption enhancer, triggering MHRA approval and a new phase in the GLP-1 obesity drug race. Full story: https://getbiobrief.com/story/wegovy-pill-oasis-4-clinical-trial-16-6-percent-weight-loss ### First Daily GLP-1 Pill Approved: Wegovy Oral Achieves 17% Weight Loss in Trial 2026-06-11 16:43:14 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 3 The MHRA’s landmark approval of oral semaglutide introduces a needle-free GLP-1 option for obesity, backed by a 17% weight-loss result in adherent patients. Healthcare providers must now navigate private-only access and patient education around strict dosing protocols. Full story: https://gethealthbrief.com/story/wegovy-pill-uk-approval-oral-semaglutide-17-percent-weight-loss ### The Cosmetic Blurring of GLP-1 Jabs: A Growing Black Market Regulatory Crisis 2026-03-25 15:52:17 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 3 The rapid transition of GLP-1 weight loss medications from clinical treatments to 'lifestyle' products is creating a regulatory vacuum exploited by black market actors. Health authorities warn that the blurring of medicine and cosmetics is driving a surge in counterfeit drugs and unmonitored usage. Full story: https://getbiobrief.com/story/glp1-cosmetic-blurring-black-market-risk ### Fatal Bacterial Outbreak in Wet Wipes Linked to Six Deaths 2026-03-08 18:24:43 · Sector: retail · Sentiment: Strongly negative · Impact: 8/10 · Sources: 2 A public health crisis has emerged in the personal care sector following six confirmed deaths linked to bacterial contamination in wet wipes. Retailers and e-commerce platforms are initiating emergency product withdrawals as investigators trace the source of the fatal pathogen. Full story: https://getretailbrief.com/story/fatal-bacterium-wet-wipes-outbreak-retail-impact ### NHS Faces Mounting Pressure to Approve High-Efficacy Cancer Therapies 2026-03-06 01:31:00 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 11 A bereaved family's national campaign has ignited a fierce debate over the NHS's refusal to fund a new treatment for aggressive cancer despite evidence of significant tumor shrinkage. The case underscores the growing tension between rapid pharmaceutical innovation and the UK's rigid cost-effectiveness appraisal frameworks. Full story: https://gethealthbrief.com/story/nhs-regulatory-pressure-aggressive-cancer-treatment ### UK Draft Rare Cancers Law Targets Incurable Brain Tumor Treatment Gaps 2026-02-27 01:23:41 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 4 The UK government is advancing a draft Rare Cancers Law designed to fast-track treatments and research for patients with incurable brain tumors. This legislative push aims to dismantle bureaucratic barriers that have historically hindered drug development and clinical trial access for rare oncological conditions. Full story: https://gethealthbrief.com/story/uk-rare-cancers-law-brain-tumors ### UK Drafts Rare Cancers Law to Accelerate Brain Tumor Treatment Access 2026-02-27 01:20:16 · Sector: legal · Sentiment: Positive · Impact: 7/10 · Sources: 4 The UK Government has introduced a landmark draft Rare Cancers Law designed to streamline regulatory pathways for incurable brain tumors and other orphan malignancies. This legislative shift aims to incentivize pharmaceutical R&D while providing patients with faster access to experimental therapies and clinical trials. Full story: https://getlegalbrief.com/story/uk-draft-rare-cancers-law-brain-tumors ### UK Medical Device Testing Hits Record High as MHRA Accelerates AI and Neurotech 2026-02-19 12:17:51 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2 The UK's Medicines and Healthcare products Regulatory Agency (MHRA) reported a record 137 clinical investigation notifications in 2025, a 32% increase over the previous year. This surge is driven by a strategic regulatory pivot toward AI-driven diagnostics and brain-computer interfaces, signaling the UK's intent to lead in high-risk medical innovation. Full story: https://gethealthbrief.com/story/uk-mhra-medical-device-testing-record-high-ai-neurotech --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.